NPPA Extends Ceiling Prices for Orthopaedic Knee Implants
The NPPA has decided to continue the current ceiling prices for primary and secondary knee replacement systems. The specific ceiling prices for primary and secondary knee replacement systems will remain unchanged for another year, i.e. from September 16, 2024 to September 15, 2025, or until the next revision.
NPPA Fixes Retail Prices For 62 Formulations
The order specifies the retail prices for a total of 62 new drugs for specified strengths and manufacturers. These prices are exclusive of Goods and Services Tax, if applicable. Manufacturers are required to submit a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and provide copies to State Drug Controllers and dealers.
NPPA Revises Ceiling Prices for Chloroquine
NPPA has further increased the ceiling price of 1 Tablet of Chloroquine 150 mg from Rs. 1.17 to Rs. 1.33. The new prices take into account a minimal increase based on the Wholesale Price Index (WPI).
Hikes In Ceiling Prices For Scheduled Formulations
The National Pharmaceutical Pricing Authority (NPPA) has issued a notification revising the ceiling prices for scheduled formulations. This action aims to regulate drug prices in the country and it takes into consideration the Wholesale Price Index (WPI) impact @0.00551% for the year 2024. These notifications were issued on August 7, 2024.
NPPA Revises Retail Prices for 70 New Drug Formulations
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices for 58 + 12 pharmaceutical formulations. These prices are exclusive of Goods and Services Tax, if applicable. These prices were notified on August 6, 2024.
NPPA Approves 15% Price Increase for Ciprofloxacin Injection by Aculife Healthcare
The National Pharmaceutical Pricing Authority (NPPA) has approved a 15% increase in the ceiling price of Ciprofloxacin Injection 200mg/100ml for M/s Aculife Healthcare Pvt. Ltd., due to the special features of their packaging. The ceiling price has been fixed as Rs. 0.23/ ml (plus applicable Goods and Services Tax). Prices for all such formulations must be revised downward if they exceed the set ceiling price plus local taxes.
NPPA Revises Retail Prices for 54 New Drug Formulations
The retail price for these specified formulations must match the specified price. Manufacturers are required to submit a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and provide copies to State Drug Controllers and dealers. Retailers and dealers must clearly display the price list provided by manufacturers to ensure it is easily accessible to customers.
NPPA Revises Ceiling Price Of Budesonide (A) +Formoterol (B)
Now, by the present corrigendum NPPA has revised the ceiling price for Budesonide (A) +Formoterol (B). The ceiling price has now been fixed as Rs. 6.95/ per dose. This applies to the dosage in the form of Inhalation (DPI) 400mcg(A) +6 mcg (B).
NPPA Fixes Ceiling Price of New Drugs and Scheduled Formulations
The National Pharmaceutical Pricing Authority (NPPA) has set maximum prices for certain new drug formulations made by specific companies. Additionally, NPPA has also fixed ceiling prices for certain scheduled formulations. The ceiling prices specified are exclusive of GST and apply to the respective dosage forms, strengths, and units detailed in the entries.
Revision In Ceiling Prices Of Coronary Stents
The new ceiling prices are Rs. 10,509.79 per unit for Bare Metal Stents and Rs. 38,267.18 per unit for Drug Eluting Stents (DES). These prices are exclusive of Goods and Services Tax (GST). Manufacturers can revise their existing MRP (Maximum Retail Price) based on the new ceiling price and WPI increase.
